JAZZ (Jazz Pharmaceuticals) Total Equity: $4,532 Mil (As of Mar. 2026)


JAZZ Jazz Pharmaceuticals PLC JAZZ
73 GF Score
Price $245.00
GF Value $150.95
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Total Equity?

Jazz Pharmaceuticals JAZZ +0.34% 73 Total Equity is $4,532 Mil as of Mar. 2026. GuruFocus rates JAZZ with a GF Score™ of 73/100 and a GF Value™ of $150.95 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Jazz Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was $4,532 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Jazz Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Total Equity Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,965.19 3,085.73 3,737.00 4,093.76 4,318.58

Jazz Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,174.89 3,706.36 3,959.03 4,318.58 4,532.30
JAZZ
73GF Score
Jazz Pharmaceuticals PLC JAZZ
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Jazz Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=11659.34-7340.756
=4,319

Jazz Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=11859.6-7327.3
=4,532

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $4,532 Mil mean?
Jazz Pharmaceuticals (JAZZ) has a Total Equity of $4,532 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Total Equity too high?
Jazz Pharmaceuticals' current Total Equity is $4,532 Mil. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Total Equity compare to BBIO and EXEL?
Jazz Pharmaceuticals' Total Equity of $4,532 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Total Equity is $4,532 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (JAZZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $150.95, compared to a current price of $245.00 — trading 62.3% above its estimated fair value. The current Total Equity is $4,532 Mil. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Jazz Pharmaceuticals (JAZZ), the current Total Equity is $4,532 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (JAZZ) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of $245.00 is trading 62.3% above its estimated GF Value™ of $150.95. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for JAZZ:

  • Total Equity: $4,532 Mil
  • GF Value™: $150.95 vs. price of $245.00 (62.3% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the JAZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for JAZZ

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$245.00
Price
$150.95
GF Value